FOLH1 and neoplasm: Mean absorbed doses for both the tumor and the kidneys were clearly lower in the case of [177Lu]Lu-PSMA-617 (3.90 and 0.05 Gy/MBq, respectively) and, the resulting tumor-to-kidney dose ratio (~87), therefore, much higher as compared to the albumin-binding radioligands (Figure 6) [19].